NASDAQ:FOLD Amicus Therapeutics (FOLD) Stock Price, News & Analysis → Collect 10%+ Dividends from AI's Explosive Growth? (From The Oxford Club) (Ad) Free fold Stock Alerts $10.14 -0.50 (-4.70%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$10.13▼$10.5750-Day Range$9.04▼$11.7552-Week Range$9.02▼$14.57Volume1.67 million shsAverage Volume2.03 million shsMarket Capitalization$3.00 billionP/E RatioN/ADividend YieldN/APrice Target$17.57 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Amicus Therapeutics alerts: Email Address Amicus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside73.3% Upside$17.57 Price TargetShort InterestBearish9.31% of Shares Sold ShortDividend StrengthN/ASustainability-1.28Upright™ Environmental ScoreNews Sentiment0.96Based on 10 Articles This WeekInsider TradingSelling Shares$75,525 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.12) to $0.19 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.10 out of 5 starsMedical Sector161st out of 915 stocksPharmaceutical Preparations Industry64th out of 430 stocks 4.4 Analyst's Opinion Consensus RatingAmicus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAmicus Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Amicus Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.31% of the outstanding shares of Amicus Therapeutics have been sold short.Short Interest Ratio / Days to CoverAmicus Therapeutics has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.Change versus previous monthShort interest in Amicus Therapeutics has recently decreased by 4.57%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAmicus Therapeutics does not currently pay a dividend.Dividend GrowthAmicus Therapeutics does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmicus Therapeutics has received a 63.50% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Fabry disease medication", "Clinical research services for genetic diseases", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Amicus Therapeutics is -1.28. Previous Next 3.3 News and Social Media Coverage News SentimentAmicus Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Amicus Therapeutics this week, compared to 4 articles on an average week.Search Interest11 people have searched for FOLD on MarketBeat in the last 30 days. This is an increase of 267% compared to the previous 30 days.MarketBeat Follows2 people have added Amicus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amicus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $75,525.00 in company stock.Percentage Held by InsidersOnly 2.20% of the stock of Amicus Therapeutics is held by insiders.Read more about Amicus Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Amicus Therapeutics are expected to grow in the coming year, from ($0.12) to $0.19 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amicus Therapeutics is -20.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amicus Therapeutics is -20.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmicus Therapeutics has a P/B Ratio of 18.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Amicus Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Oxford ClubAmerica's #1 AI Dividend Stock RevealedIncome expert Marc Lichtenfeld has a special gift reserved just for you... It's his brand-new "AI Income Playbook" - and it's yours FREE!Click here now to claim your FREE copy of Marc's AI playbook. About Amicus Therapeutics Stock (NASDAQ:FOLD)Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Read More FOLD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FOLD Stock News HeadlinesJune 14 at 1:03 AM | americanbankingnews.comQ2 2024 EPS Estimates for Amicus Therapeutics, Inc. Increased by Zacks Research (NASDAQ:FOLD)June 13 at 11:55 AM | globenewswire.comIn NCLA Amicus Win, Supreme Court Overturns NLRB-Specific Preliminary Injunction StandardJune 11, 2024 | globenewswire.comIn NCLA Amicus Win, Tenth Circuit Clears Path to Toppling Intrusive Dog Kennel Inspection RegimeJune 7, 2024 | americanbankingnews.comBrokerages Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) PT at $17.57June 5, 2024 | globenewswire.comIn NCLA Amicus Win, Fifth Circuit Topples SEC's Unlawful Effort to Regulate Private FundsJune 5, 2024 | globenewswire.comAmicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 24, 2024 | msn.comDo Options Traders Know Something About Amicus (FOLD) Stock We Don't?May 20, 2024 | seekingalpha.comAmicus Therapeutics: Too Cheap At Under $10 A ShareMay 14, 2024 | msn.comGuggenheim Upgrades Amicus Therapeutics (FOLD)May 14, 2024 | markets.businessinsider.comEvaluating Amicus Therapeutics: Insights From 6 Financial AnalystsMay 10, 2024 | finance.yahoo.comAmicus Therapeutics Inc (FOLD) Q1 2024 Earnings: Surpasses Revenue Estimates and Projects ...May 10, 2024 | finance.yahoo.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2024 Earnings Call TranscriptMay 9, 2024 | investorplace.comFOLD Stock Earnings: Amicus Therapeutics Beats EPS, Misses Revenue for Q1 2024May 9, 2024 | washingtonpost.comAmicus Therapeutics: Q1 Earnings SnapshotMay 9, 2024 | globenewswire.comAmicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate UpdatesMay 8, 2024 | globenewswire.comAmicus Therapeutics to Present at the Bank of America 2024 Health Care ConferenceMay 8, 2024 | barrons.comAmicus Therapeutics Inc.May 1, 2024 | globenewswire.comAmicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024April 14, 2024 | nasdaq.comAmicus Therapeutics Becomes Oversold (FOLD)March 30, 2024 | msn.comNevada’s Lee joins on to Amicus Brief in SCOTUS abortion caseMarch 29, 2024 | msn.comNevada’s Lee, Cortez Masto join on to Amicus Brief in SCOTUS abortion caseMarch 20, 2024 | globenewswire.comAmicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) ReportMarch 16, 2024 | ca.finance.yahoo.comFOLD Jul 2024 12.000 callMarch 7, 2024 | finance.yahoo.comFOLD Oct 2024 12.000 callMarch 7, 2024 | finance.yahoo.comFOLD Jan 2025 12.000 putSee More Headlines Receive FOLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/15/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:FOLD CUSIP03152W10 CIK1178879 Webwww.amicusrx.com Phone(215) 921-7600Fax609-662-2001Employees517Year Founded2002Price Target and Rating Average Stock Price Target$17.57 High Stock Price Target$22.00 Low Stock Price Target$13.00 Potential Upside/Downside+73.3%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-151,580,000.00 Net Margins-34.73% Pretax Margin-33.17% Return on Equity-77.08% Return on Assets-13.79% Debt Debt-to-Equity Ratio2.97 Current Ratio3.03 Quick Ratio2.61 Sales & Book Value Annual Sales$399.36 million Price / Sales7.52 Cash FlowN/A Price / Cash FlowN/A Book Value$0.55 per share Price / Book18.44Miscellaneous Outstanding Shares296,200,000Free Float289,683,000Market Cap$3.00 billion OptionableOptionable Beta0.74 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. Bradley L. Campbell M.B.A. (Age 48)CEO, President & Director Comp: $984.09kMs. Ellen S. Rosenberg (Age 61)Chief Legal Officer & Corporate Secretary Comp: $733.94kMr. David M. Clark (Age 49)Chief People Officer Comp: $701.39kDr. Jeffrey P. Castelli (Age 52)Chief Development Officer Comp: $709.64kMr. Simon Nicolas Reade Harford (Age 64)Chief Financial Officer Ms. Samantha Prout (Age 46)Chief Accounting Officer & Controller Dr. Jill Weimer Ph.D.Chief Science OfficerAndrew FaughnanSenior Director of Investor RelationsMr. Patrik S. Florencio Esq.Global Chief Compliance & Risk OfficerMs. Diana MooreHead of Global Corporate CommunicationsMore ExecutivesKey CompetitorsBiohavenNYSE:BHVNArrowhead PharmaceuticalsNASDAQ:ARWRPerrigoNYSE:PRGOBausch Health CompaniesNYSE:BHCTurning Point TherapeuticsNASDAQ:TPTXView All CompetitorsInsiders & InstitutionsTeachers Retirement System of The State of KentuckySold 35,477 shares on 5/28/2024Ownership: 0.016%Artal Group S.A.Sold 3,514,588 shares on 5/17/2024Ownership: 0.342%Comerica BankSold 9,544 shares on 5/17/2024Ownership: 0.032%Walleye Trading LLCSold 8,700 shares on 5/17/2024Ownership: 0.000%California State Teachers Retirement SystemSold 9,452 shares on 5/16/2024Ownership: 0.077%View All Insider TransactionsView All Institutional Transactions FOLD Stock Analysis - Frequently Asked Questions Should I buy or sell Amicus Therapeutics stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" FOLD shares. View FOLD analyst ratings or view top-rated stocks. What is Amicus Therapeutics' stock price target for 2024? 8 Wall Street analysts have issued twelve-month price targets for Amicus Therapeutics' shares. Their FOLD share price targets range from $13.00 to $22.00. On average, they predict the company's share price to reach $17.57 in the next year. This suggests a possible upside of 73.3% from the stock's current price. View analysts price targets for FOLD or view top-rated stocks among Wall Street analysts. How have FOLD shares performed in 2024? Amicus Therapeutics' stock was trading at $14.19 on January 1st, 2024. Since then, FOLD stock has decreased by 28.5% and is now trading at $10.14. View the best growth stocks for 2024 here. When is Amicus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our FOLD earnings forecast. How were Amicus Therapeutics' earnings last quarter? Amicus Therapeutics, Inc. (NASDAQ:FOLD) announced its quarterly earnings data on Thursday, May, 9th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.04. The biopharmaceutical company earned $110.40 million during the quarter, compared to analyst estimates of $111.19 million. Amicus Therapeutics had a negative net margin of 34.73% and a negative trailing twelve-month return on equity of 77.08%. The firm's quarterly revenue was up 27.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.18) EPS. What ETFs hold Amicus Therapeutics' stock? ETFs with the largest weight of Amicus Therapeutics (NASDAQ:FOLD) stock in their portfolio include Sovereigns Capital Flourish Fund (SOVF), Invesco Biotechnology & Genome ETF (PBE), Global X Guru Index ETF (GURU), Virtus LifeSci Biotech Products ETF (BBP), WisdomTree BioRevolution Fund (WDNA), SPDR S&P Biotech ETF (XBI), First Trust Innovation Leaders ETF (ILDR) and Principal Healthcare Innovators ETF (BTEC). What guidance has Amicus Therapeutics issued on next quarter's earnings? Amicus Therapeutics issued an update on its FY 2024 earnings guidance on Thursday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $499.2 million-$519.2 million, compared to the consensus revenue estimate of $530.0 million. What is John F. Crowley's approval rating as Amicus Therapeutics' CEO? 21 employees have rated Amicus Therapeutics Chief Executive Officer John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among the company's employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Amicus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX). Who are Amicus Therapeutics' major shareholders? Amicus Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.52%), Janus Henderson Group PLC (4.66%), Redmile Group LLC (4.48%), William Blair Investment Management LLC (3.89%), Healthcare of Ontario Pension Plan Trust Fund (0.73%) and Price T Rowe Associates Inc. MD (0.47%). Insiders that own company stock include Bradley L Campbell, Burke W Whitman, Burke W Whitman, Daphne Quimi, David Michael Clark, Ellen Rosenberg, Ellen Rosenberg, Jeff Castelli, John F Crowley, John F Crowley, Margaret G Mcglynn, Michael Raab and Samantha Prout. View institutional ownership trends. How do I buy shares of Amicus Therapeutics? Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FOLD) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersDiscover How to Turn $10,000 into $1 MillionToday, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRIL...Paradigm Press | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amicus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
